October 2024 in “American Journal of Case Reports” Baricitinib improved hair loss and arthritis in a lupus patient.
July 2024 in “Journal of Investigative Dermatology” DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.
17 citations
,
October 2006 in “Molecular and Cellular Endocrinology” The L457(3.43)R mutation in the human lutropin receptor causes increased activity and hormone insensitivity, leading to precocious puberty.
October 2024 in “Frontiers in Oncology” A new gene mutation linked to Olmsted syndrome may increase cancer risk, suggesting the need for ongoing patient monitoring.
53 citations
,
June 1993 in “Proceedings of the National Academy of Sciences of the United States of America” LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.
14 citations
,
August 2018 in “Journal of Pharmaceutical and Biomedical Analysis”
136 citations
,
April 2013 in “Clinical Cancer Research” The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.
2 citations
,
July 1996 in “Hair transplant forum international” The document's conclusion cannot be provided because the document is not accessible or understandable.
June 2024 in “International Journal of Pharmaceutical Quality Assurance” The method accurately and quickly measures silodosin and dutasteride in mixtures.
3 citations
,
December 2021 in “Frontiers in endocrinology” A new mutation in the DCAF17 gene was found in a Chinese family, causing Woodhouse-Sakati syndrome and diabetes.
March 2005 in “Current Prostate Reports”
September 2023 in “Journal of The American Academy of Dermatology” Baricitinib shows promise in treating severe hair loss.
September 2023 in “Journal of The American Academy of Dermatology” Baricitinib treatment can help regrow scalp hair and eyebrows or eyelashes in people with severe alopecia areata.
September 2025 in “Cosmetics” Genetic profiling can improve androgenetic alopecia treatment by predicting drug response and minimizing side effects.
The document doesn't provide enough information to summarize.
November 2025 in “Journal of Investigative Dermatology” August 2024 in “American Journal of Medical Genetics Part A” Variants in the CCDC47 gene are linked to trichohepatoneurodevelopmental syndrome.
5 citations
,
March 2019 in “Journal of lipid research” New probes were created to effectively measure specific enzymes involved in fat metabolism, which could help develop new drugs.
Secukinumab treatment may cause HBV reactivation and hair discoloration.
April 2023 in “Journal of Investigative Dermatology” The document's conclusion cannot be provided because the content is not accessible.
1 citations
,
January 2013 in “MedChemComm” PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
13 citations
,
January 2013 in “Applied and Environmental Microbiology” A gene in Sebekia benihana, CYP-sb21, is needed for a specific reaction on the drug Cyclosporine A, which could be important for hair growth without affecting the immune system.
May 2023 in “Elsevier eBooks” The document's conclusion cannot be provided because the document is not readable or understandable.
1 citations
,
May 2022 in “Frontiers in Pharmacology” Astilbin can potentially calm overactive immune responses, like in Type 1 Diabetes, by suppressing certain cell activities and reducing inflammation.
January 2004 in “Drug Development and Industrial Pharmacy” GI197111X is best dissolved in Capmul MCM for trials.
July 2004 in “Hair transplant forum international” The document's conclusion cannot be provided because the document is not available for parsing.
1 citations
,
January 2013 in “Hair therapy & transplantation” The document does not provide information about hair loss treatment.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
December 2013 in “Urology reports (St - Petersburg)” Sonirid Duo effectively treats benign prostatic hyperplasia.
22 citations
,
May 2011 in “European Journal of Cancer” The drug combination was safe and showed promise in treating advanced tumors.